RhumbLine Advisers’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $799K | Sell |
|
|||||
|
2025
Q2 | $692K | Buy |
|
|||||
|
2025
Q1 | $455K | Buy |
|
|||||
|
2024
Q4 | $647K | Buy |
|
|||||
|
2024
Q3 | $2.35M | Sell |
|
|||||
|
2024
Q2 | $1.9M | Buy |
|
|||||
|
2024
Q1 | $2.29M | Buy |
|
|||||
|
2023
Q4 | $1.26M | Sell |
|
|||||
|
2023
Q3 | $1.04M | Sell |
|
|||||
|
2023
Q2 | $1.32M | Buy |
|
|||||
|
2023
Q1 | $1.2M | Buy |
|
|||||
|
2022
Q4 | $1.27M | Buy |
|
|||||
|
2022
Q3 | $879K | Buy |
|
|||||
|
2022
Q2 | $560K | Buy |
|
|||||
|
2022
Q1 | $864K | Buy |
|
|||||
|
2021
Q4 | $813K | Sell |
|
|||||
|
2021
Q3 | $561K | Buy |
|
|||||
|
2021
Q2 | $574K | Sell |
|
|||||
|
2021
Q1 | $842K | Buy |
|
|||||
|
2020
Q4 | $960K | Buy |
|
|||||
|
2020
Q3 | $271K | Sell |
|
|||||
|
2020
Q2 | $294K | Buy |
|